AURORA, Colo. – A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD). Published in the December issue of the Journal of Biological Chemistry, researchers characterize...
Latest News
MIAMI, Florida – Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in Nature Medicine. This combined approach, developed by Florida International University cancer researcher...
DAVENPORT – The Sunshine Foundation, an organization that grants wishes to sick children, will bring to Central Florida 14 young people, mostly children, who were born with progeria, an illness that causes them to age prematurely. The organization’s annual Progeria Reunion will include a picnic and game day at the...
Seven years after the passage of a law advancing the interests of persons afflicted with rare diseases, patients, and other stakeholder groups are still clamoring for government support in terms of adequate funding and implementation of the Integrated Rare Diseases Management Program Strategic Plan. “Persons suffering from rare diseases, sometimes...
CHICAGO, Illinois – Researchers have identified a new way to screen genes that cause several different types of cancers to grow, identifying particularly promising targets for precision oncology in oral and esophageal squamous cancers. The study, published in this month’s issue of Cell Reports, used 3-dimensional models of organ tissues called organoids...
WALTHAM, Mass. — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson’s disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a...
Brentford, UK – GSK plc (LSE/NYSE: GSK) today announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma. These data were presented...
MISSISSAUGA, Canada – GSK announced that Health Canada has accepted into review the New Drug Submission (NDS) for momelotinib, a potential new medicine with a differentiated mechanism of action that may help address the significant medical needs of myelofibrosis patients, especially those with anemia. The NDS is based on key...
London, UK – GSK plc (LSE/NYSE: GSK) today announced that GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC), has received Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for the treatment of pulmonary neuroendocrine carcinoma (NEC), a category of cancer that includes small-cell lung cancer (SCLC). The ODD was...
BEVERLY HILLS, Calif.- GT Biopharma, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology: TriKE™ for cancer and infectious diseases, today announced the addition of a new clinical trial site for its ongoing...